期刊文献+

2010~2012年我院质子泵抑制剂的应用分析 被引量:3

Utilization of proton pump inhibitors in a hospital during the period of 2010~2012
下载PDF
导出
摘要 目的 了解和分析我院2010~2012年质子泵抑制剂的临床应用情况,为临床安全高效、经济合理用药提供参考依据.方法 从医院计算机管理系统中调出我院2010~2012年质子泵抑制剂的使用情况,按金额排序法和用药频度排法,对质子泵抑制剂的应用品种、销售金额、用药频度、日均费用进行统计和分析.结果 2010~2012年,质子泵抑制剂总的销售金额逐年增长.泮托拉唑DDDs连续三年居首位,其销售金额亦连续两年居首位.大多药物的序号比值接近于1.结论 该院质子泵抑制剂的销售金额与用药频度的同步性较好,应用基本合理,亦有需要改进之处. Objective To analyze the application of proton pump inhibitors in a hospital from 2010 to 2012, and to provide reference to rational drug use in clinic. Methods Make statistics of the variety, consumption amount, sales amount, DDDs and daily costs of proton pump inhibitors. Results From 2010 to 2012 ,the total sale amount of proton pump inhibi- tors increased year by year. The total DDDs of pantoprazole ranked the first continuously for three years, and sales amount ranked the first continuously for two years. The ratio of sales volume sequencing to that of DDDs of drugs were near to 1. Conclusion The sales amount and DDDs of proton pump inhibitors in the hospital had a good consistency. Rational uti- lization was found in the hospital.
出处 《药学研究》 CAS 2013年第10期608-610,共3页 Journal of Pharmaceutical Research
关键词 质子泵抑制剂 限定日剂量(DDD) 用药频度(DDDs) 日均费用(DDDc) Proton pump inhibitors DDD DDDs DDDc
  • 相关文献

参考文献7

二级参考文献40

  • 1宗育杉,吴胜群,李志军.大鼠应激性溃疡发病机制及其防治方法的研究[J].中国危重病急救医学,1995,7(5):265-267. 被引量:12
  • 2农汉军,郑文军,马志雄,冯凤萍,黄爱红.胃镜下云南白药联合兰索拉唑治疗消化性溃疡出血42例临床观察[J].右江民族医学院学报,2006,28(3):362-364. 被引量:13
  • 3Baldi F. Lansoprazole ora-dispersible tablet :pharmacokinetics and therapeutic use in acid-ralated disorders. Drugs,2005,65:1419-1426.
  • 4Andersson T, Hss RK, Bredberg E,et al. Pharmacokinetics and pharmacodynamics of esomeprazole,the S-isomer of omeprazole. Aliment Pharmacol Ther,2001,15 : 1563-1559.
  • 5Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, et al. Esomeprazole 40 mg Provides Improved Intragastric Acid Control as Compared with Lansoprazole 30 mg and Rabeprazole 20 mg in Healthy Volunteers. Digestion ,2003,68:184-188.
  • 6Li XQ, Andersso TB,Ahlstrom M,et al. Comparison of inhibitory effects of the proton pump-inhibitory drugs omeprazole, asomeprazole, lansoprazole,pantoprazole,and rabeprazole on human cytochrome P450 activities. DMD,2004,32:821-827.
  • 7Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg,pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms, Eur J Clin Pharmacol, 2004,60 : 531 - 539.
  • 8Takahashi S, Yamazaki T, Okabe S. Leminoprazole protects cultured gastric mucosal cells against damage caused by ethanol, indometacin and taurocholate. Pharmacology, 1997,54 : 118-126.
  • 9Takahashi S, Okabe S. Mechanism by which orally administered leminoprazole stimulates mucus synthesis in rats. Pharmacology, 1998,57:47-56.
  • 10Galmiche JP, Broley Des Varannes S, et al. Tenatoprazole, a novel proton pump inhibitor with a rolonged plasma half-life:effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther,2004,19:655-662.

共引文献61

同被引文献31

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部